Hepatitis C virus infection among injecting drug users in the Czech Republic - Prevalence and associated factors

European Addiction Research

Volumn 12, Issue 3, 2006, Pages 151-160

  Zabransky, Tomas ^a   Mravcik, Viktor ^a   Korcisova, Blanka ^a   Rehak, Vratislav ^a  

^a Czech National Focal Point for Drugs and Drug Addiction   (Czech Republic)

Author keywords

Epidemiology; Injecting drug use; Logistic regression model; Prison; Seroprevalence; Viral hepatitis C

Indexed keywords

HEPATITIS C ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BLOOD TESTIS BARRIER; CALCULATION; CZECH REPUBLIC; DEMOGRAPHY; FEMALE; HEPATITIS C; HUMAN; INTERVIEW; INTRAVENOUS DRUG ABUSE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PRISON; SNOWBALL SAMPLE; STRUCTURED QUESTIONNAIRE; UNIVARIATE ANALYSIS;

CROSS-SECTIONAL STUDIES; CZECH REPUBLIC; HEPATITIS C; HUMANS; LOGISTIC MODELS; PREVALENCE; QUESTIONNAIRES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33745207832     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092117     Document Type: Article

References (42)

1. Heintges T, Wands JR: Hepatitis C virus: epidemiology and transmission. Hepatology 1997;26:521-526.
2. Yen T, Keeffee EB, Ahmed A: The epidemiology of hepatitis C virus infection. J Clin Gastroenterol 2003;36:47-53.
3. Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L: Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 2002;129:577-585.
4. Mathei C, Buntinx F, van Damme P: Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepat 2002;9:157-173.
5. Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, Giles W, Gow P, Kaldor J, Loveday S, Powell E, Spencer J, Wodak A: Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol 2003;32:717-724.
6. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ: Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002;156:761-773.
7. Caiaffa WT, Mingoti SA, Proietti FA, Carneiro-Proietti AB, Silva RC, Lopes AC, Doneda D: Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil project. J Urban Health 2003;80:106-114.
8. Ruan YH, Hong KX, Liu SZ, He YX, Zhou F, Qin GM, Chen KL, Xing H, Chen JP, Shao YM: Community-based survey of HCV and HIV coinfection in injection drug abusers in Sichuan Province of China. World J Gastroen-terol 2004;10:1589-1593.
9. Verachai V, Phutiprawan T, Theamboonlers A, Chinchai T, Tanprasert S, Haagmans BL, Osterhaus AD, Poovorawan Y: Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand. Southeast Asian J Trop Med Public Health 2002;33:849-851.
10. Wiessing L, Roy K, Sapinho D, Hay G, Taylor A, Goldberg D, Hartnoll R: Surveillance of hepatitis C infection among injecting drug users in the European Union; in Jager J, Limburg L, Kretzschmar M, Postma M, Wiessing L (eds): Hepatitis C and Injecting Drug Use: Impact, Costs and Policy Options. Lisbon, European Monitoring Centre for Drugs and Drug Addiction, 2004, pp 94-132.
11. Backmund M, Meyer K, Wachtler M, Eichenlaub D: Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol 2003;18:563-568.
12. Quaglio G, Lugoboni F, Pajusco B, Sarti M, Talamini G, Lechi A, Mezzelani P, Des Jarlais DC: Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clin Infect Dis 2003;37:33-40.
13. Rhodes T: Researching hidden populations; in Fountain J (ed): Understanding and Responding to Drug Use the Role of Qualitative Research, ed 1. Luxembourg, Office for Official Publications of the European Communities, 2000, pp 34-45.
14. EMCDDA: Study to Obtain Comparable National Estimates of Problem Drug Use Prevalence for all EU Member States. Lisbon, EMCDDA, 1999 Oct (CT.97.EP.04).
15. Mravčík V, Korčišová B, Lejčková P, Miovská L, Škrdlantová E, Petroš O, Radimecký J, Sklenář V, Gajdošíková H, Vopravil J: Výroční zpráva o stavu ve věcech drog v České republice v roce 2003 [The Czech Republic - Drug Situation 2003]. Annual Reports ed. Praha: Úřad vlády ČR [Office of the Czech Government], 2004.
16. Generální ředitelství Vězeň ské služby [Directorate-general of the Czech prison services]. Výsledky vyšetření na infekčni nemoci v českých věznicích v roce 2002 [Results of the seroprevalence examinations in the Czech prisons]. Vězeňská služba ČR [Czech Prison Services], 2003.
17. Mravčík V, Zábranský T: Dotazní kový průzkum injekčního užívá ní drog v lékárnách České republiky [The Estimate of Intravenous Drug Use in Czech Republic: Questionnaire Survey in Pharmacies]. Adiktologie. 2001;1:11-21; ISSN: 1213-3841.
18. Miovský M, Sochůrek J, Gajdošiková H: Analýza současného stavu užívá ní nelegálních drog ve věznicích [Analysis of the status quo in drug use in Czech prisons]; in Miovský M, Spirig H, Havlíčková M (eds): Vězeňství a nelegální drogy [Czech Prison System and Illegal Drugs]. Monografie ed. Praha, Narodní monitorovací středisko pro drogy a drogové závislosti/Úřad vlády ČR; 2003;c2003. pp 20-39.
19. Griffiths P, Nilson M, Carpentier C, Merino PP: (EMCDDA). Treating drug users in prisons - a critical area for health promotion and crime reduction policy. EMCDDA. Drugs Focus - Briefing. 2003;2:1-4.
20. Mravčík V, Šebáková H: Séroprevalence virových hepatitid typu B a C u injekčních uživatelů drog - projekt IKTERUS [Seroprevalence HBV and HCV in IDUs - IKTERUS Project]. Adiktologie 2002;2:13-35.
21. Trmal J, Kellerová J, Koblížková R: Dopad výměnného programu injekčních jehel a stříkaček na šíření virové hepatitidy typu C [The Impact of Needle Exchange Programmes at HVC Spreading]. Epidemiol Mikrobiol Imunol 1999;IIL(4).
22. Řehák V, Krekulová L: Virové hepatitidy u injekčnich uživatelů psychoaktivních látek [Viral hepatitis at IDUs]. Adiktologie 2002;2:40-49.
23. Wilczek H, Urbanek P: Prevalence sérologických markerů infekcí virem hepatitidy B a hepatitidy C u drogově závislých osob léčených v pražském metadonovém centru Drop in o.p.s. [Prevalence of serological markers of viral hepatitis B and hepatitis C in drug-dependent individuals treated at the Drop Methadone Center in Prague]. Cas Lek Cesk 2003;142:240-243.
24. Klusoňová H, Štěpánová V, Čížek J, Plisková L: Virové hepatitidy u problémových uživatelů návykových látek v ČR [Viral hepatitis in users of addictive drugs in the Czech Republic]. Epidemiol Mikrobiol Imunol 2004;53:47-54.
25. Lejčková P, Mravčík V, Radimecký J: Srovnání užívání drog a jeho dopadů v krajích České republiky - Situační analýza v širším demografickém a socioekonomickém kontextu, ed 1. [The comparison of illegal drug use and its impacts in Czech regions - Situation analysis in broader demographic and socioeconomic context, ed 1]. Praha/Prague, Úřad vlády ČR [Office of the Czech Government], 2004.
26. Zábranský T, Radimecký J, Mravčík V, Gajdošíková H, Csémy L, Vopravil J: Report on the Drug Situation 2000 - Czech Republic. Prague and Lisbon: National Drug Commission Czech Republic and European Monitoring Centre on Drugs and Drug Addiction, 2002, Feb.
27. Stein JA, Nyamathi A: Correlates of hepatitis C virus infection in homeless men: a latent variable approach. Drug Alcohol Depend 2004;75:89-95.
28. Samuel MC, Doherty PM, Bulterys M, Jenison SA: Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 2001;127:475-484.
29. Dore GJ, Law M, MacDonald M, Kaldor JM: Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003;26:171-184.
30. Miller CL, Johnston C, Spittal PM, Li K, Laliberte N, Montaner JS, Schechter MT: Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002;36:737-742.
31. Murray KF, Richardson LP, Morishima C, Owens JW, Gretch DR: Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics 2003;111:153-157.
32. Zábranský T: Czech drug laws as arena of drug policy battle. J Drug Issues 2004;34:661-686.
33. Mravčík V, Šebáková H: Vyšetření HIV protilátek u klientů poradny AIDS Okresní hygienické stanice Karviná v letech 1993-2000 [HIV antibodies testing in AIDS counselling service of Hygienic Station Karvina 1993-2000]. Epidemiol Mikrobiol Imunol 2002;51.
34. Allison PD: Missing Data. Sage, Thousand Oaks, 2002.
35. Kalton G: Introduction to Survey Sampling. Sage, Thousand Oaks, 1983.
36. Salganik MJ, Heckathorn DD: Sampling and estimation in hidden population using respondent-driven sampling. Sociol Methodol 2004.
37. Weatherby NL, Needle R, Cesari H, Booth R, McCoy CB, Watter JK, Williams M, Chitwood DD: Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Eval Program Plann 1994;17:347-355.
38. World Health Organization: Joint United Nations Programme on HIV/AIDS (UNAIDS) - WHO - Revised recommendations for the selection and use of HIV antibody tests. Weekly Epidemiol Rec 1997;72:81-86.
39. World Health Organization: The importance of simple/rapid assays in HIV testing (WHO/UNAIDS recommendations). Weekly Epidemiol Rec 1998;73:321-326.
40. Centers for Disease Control: Rapid testing in non-clinical settings; in CDC, PNC: Advancing HIV Prevention: Interim Technical Guidance for Selected Interventions, ed 1. Washington, Centers for Disease Control, 2003.
41. Zábranský T, Miovský M, Mravčík V, Gajdošíková H: Projekt Copernicus: Global Approach on Drugs - České substudie mezinárodního projektu - závěrečná zpráva, 2001, p 160.
42. Miovský M, Zábranský T: Přehled výsledků substudie provedené s uživateli nelegálních psychoaktivních látek a s pracovníky zdravotnických zařízení a poskytovateli služeb uživatelům nelegálních drog [Overview of PAD Qualitaive Substudy Results - Drug Users and Care and Treatment Providers]. Substudie Analýzy Dopadů Novelizace Drogové Legislativy v ČR [Substudies of the Impact Analysis Project of New Drug Legislation]. Adiktologie 2001;1(suppl):41-75.